Incyte has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s ...

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the immuno ...

Incyte Corporation (($CC:INCY.CUR)) announced an update on their ongoing clinical study. Incyte Corporation recently completed a Phase 2 clinical ...

Incyte Corporation (($CC:INCY.CUR)) announced an update on their ongoing clinical study. Incyte Corporation recently updated its clinical study ...

Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of September: Cantor Global Healthcare Conference on Wednesday, Se ...

Incyte (Nasdaq:INCY) today announced that Christiana Stamoulis will step down from her role as Executive Vice President and ...

Incyte posts strong Q2 results driven by Jakafi and Opzelura growth, lifts 2025 guidance despite challenges in future product development.

Incyte (Nasdaq:INCY) today reports 2025 second quarter financial results, and provides a status update on the Company’s clinical development portfolio.

Incyte INCY is set to give its latest quarterly earnings report on Tuesday, 2025-07-29. Here's what investors need to know before the announcement. Analysts estimate that Incyte will report an ...

WILMINGTON, Del. (AP) — WILMINGTON, Del. (AP) — Incyte Corp. (INCY) on Tuesday reported second-quarter net income of $405 million.